Login to Your Account



Hedgepath sows seeds of itraconazole-based anticancer program

By Michael Fitzhugh
Staff Writer

Wednesday, August 3, 2016

Interim results from a phase IIb trial testing a proprietary formulation of the anti-fungal drug itraconazole for the treatment of Gorlin syndrome reduced tumor burden by more than 30 percent in eight of 13 patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription